Molecular apocrine tumours in EORTC 10994/BIG 1-00 phase III study: pathological response after neoadjuvant chemotherapy and clinical outcomes
Background We explored, within the EORTC10994 study, the outcomes for patients with molecular apocrine (MA) breast cancer, and defined immunohistochemistry (IHC) as androgen-receptor (AR) positive, oestrogen (ER) and progesterone (PR) negative. We also assessed the concordance between IHC and gene e...
Gespeichert in:
| Veröffentlicht in: | British journal of cancer 2019-04, Vol.120 (9), p.913-921 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 921 |
|---|---|
| container_issue | 9 |
| container_start_page | 913 |
| container_title | British journal of cancer |
| container_volume | 120 |
| creator | Bonnefoi, Hervé MacGrogan, Gaetan Poncet, Coralie Iggo, Richard Pommeret, Fanny Grellety, Thomas Larsimont, Denis Bécette, Véronique Kerdraon, Olivier Bibeau, Frédéric Ghnassia, Jean-Pierre Picquenot, Jean-Michel Thomas, Jeremy Tille, Jean-Christophe Slaets, Leen Bodmer, Alexandre Bergh, Jonas Cameron, David |
| description | Background
We explored, within the EORTC10994 study, the outcomes for patients with molecular apocrine (MA) breast cancer, and defined immunohistochemistry (IHC) as androgen-receptor (AR) positive, oestrogen (ER) and progesterone (PR) negative. We also assessed the concordance between IHC and gene expression arrays (GEA) in the identification of MA cancers.
Methods
Centrally assessed biopsies for AR, ER, PR, HER2 and Ki67 by IHC were classified into six subtypes: MA, triple-negative (TN) basal-like, luminal A, luminal B HER2 negative, luminal B HER2 positive and “other”. The two main objectives were the pCR rates and survival outcomes in the overall MA subtype (and further divided by HER2 status) and the remaining five subtypes.
Results
IHC subtyping was obtained in 846 eligible patients. Ninety-three (11%) tumours were classified as the MA subtype. Both IHC and GEA data were available for 64 patients. In this subset, IHC concordance was 88.3% in identifying MA tumours compared with GEA. Within the MA subtype, pCR was observed in 33.3% of the patients (95% CI: 29.4–43.9) and the 5-year recurrence-free interval was 59.2% (95% CI: 48.2–68.6). Patients with MA and TN basal-like tumours have lower survival outcomes.
Conclusions
Irrespective of their HER2 status, the prognosis for MA tumours remains poor and adjuvant trials evaluating anti-androgens should be considered. |
| doi_str_mv | 10.1038/s41416-019-0420-y |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_swepu</sourceid><recordid>TN_cdi_swepub_primary_oai_swepub_ki_se_481098</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2196514044</sourcerecordid><originalsourceid>FETCH-LOGICAL-c592t-416bb8d97f0968a21a536cd948240c679f7e49d36eb9802c3fbc385101b2dd913</originalsourceid><addsrcrecordid>eNp1Uk1v1DAQjRCIbgs_gAuyxAUOoWPHcWwOSGVV2pUWVULlbDmOs8mS2MFOFu2f6G_G2922tFJPHs-8N58vSd5h-Iwh46eBYopZClikQAmk2xfJDOcZSTEnxctkBgBFCoLAUXIcwjp-BfDidXKUARfRZLPk5ofrjJ465ZEanPatNWicejf5gFqLzq9-Xs8RBiHo6bfFBcIpABoaFQxaLBYojFO1_YIGNTauc6tWqw55EwZnI0DVo_HIGqeq9bRRdkS6Mb0bG-PVsEXKVkh3rb0luWnUrjfhTfKqVl0wbw_vSfLr-_n1_DJdXl0s5mfLVOeCjGmcuix5JYoaBOOKYJVnTFeCckJBs0LUhaGiypgpBQeis7rUGc8x4JJUlcDZSZLu84a_ZphKOfi2V34rnWrlwfU7WkZSHofnES-exQ_eVQ-kOyKmwIEySiP3654bAb2ptLGjV93jFI8itm3kym0kKzLK8l3xT_sEzRPa5dlS7nxACCc5Z5vdYB8Pxbz7M5kwyr4N2nSdioeYgiRYsDz2dtvXhyfQdTy7jWuXhOCC5jxneUThPUp7F4I39X0HGOROhXKvQhlVKHcqlNvIef__xPeMO9lFADmsM4bsyviH0s9n_QdKvukp</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2217458565</pqid></control><display><type>article</type><title>Molecular apocrine tumours in EORTC 10994/BIG 1-00 phase III study: pathological response after neoadjuvant chemotherapy and clinical outcomes</title><source>PubMed (Medline)</source><source>MEDLINE</source><source>SpringerLink</source><source>SWEPUB Freely available online</source><source>EZB Electronic Journals Library</source><creator>Bonnefoi, Hervé ; MacGrogan, Gaetan ; Poncet, Coralie ; Iggo, Richard ; Pommeret, Fanny ; Grellety, Thomas ; Larsimont, Denis ; Bécette, Véronique ; Kerdraon, Olivier ; Bibeau, Frédéric ; Ghnassia, Jean-Pierre ; Picquenot, Jean-Michel ; Thomas, Jeremy ; Tille, Jean-Christophe ; Slaets, Leen ; Bodmer, Alexandre ; Bergh, Jonas ; Cameron, David</creator><creatorcontrib>Bonnefoi, Hervé ; MacGrogan, Gaetan ; Poncet, Coralie ; Iggo, Richard ; Pommeret, Fanny ; Grellety, Thomas ; Larsimont, Denis ; Bécette, Véronique ; Kerdraon, Olivier ; Bibeau, Frédéric ; Ghnassia, Jean-Pierre ; Picquenot, Jean-Michel ; Thomas, Jeremy ; Tille, Jean-Christophe ; Slaets, Leen ; Bodmer, Alexandre ; Bergh, Jonas ; Cameron, David ; EORTC 10994/BIG 1-00 study investigators ; and on behalf of the EORTC 10994/BIG 1-00 study investigators</creatorcontrib><description>Background
We explored, within the EORTC10994 study, the outcomes for patients with molecular apocrine (MA) breast cancer, and defined immunohistochemistry (IHC) as androgen-receptor (AR) positive, oestrogen (ER) and progesterone (PR) negative. We also assessed the concordance between IHC and gene expression arrays (GEA) in the identification of MA cancers.
Methods
Centrally assessed biopsies for AR, ER, PR, HER2 and Ki67 by IHC were classified into six subtypes: MA, triple-negative (TN) basal-like, luminal A, luminal B HER2 negative, luminal B HER2 positive and “other”. The two main objectives were the pCR rates and survival outcomes in the overall MA subtype (and further divided by HER2 status) and the remaining five subtypes.
Results
IHC subtyping was obtained in 846 eligible patients. Ninety-three (11%) tumours were classified as the MA subtype. Both IHC and GEA data were available for 64 patients. In this subset, IHC concordance was 88.3% in identifying MA tumours compared with GEA. Within the MA subtype, pCR was observed in 33.3% of the patients (95% CI: 29.4–43.9) and the 5-year recurrence-free interval was 59.2% (95% CI: 48.2–68.6). Patients with MA and TN basal-like tumours have lower survival outcomes.
Conclusions
Irrespective of their HER2 status, the prognosis for MA tumours remains poor and adjuvant trials evaluating anti-androgens should be considered.</description><identifier>ISSN: 0007-0920</identifier><identifier>ISSN: 1532-1827</identifier><identifier>EISSN: 1532-1827</identifier><identifier>DOI: 10.1038/s41416-019-0420-y</identifier><identifier>PMID: 30899086</identifier><language>eng</language><publisher>London: Nature Publishing Group UK</publisher><subject>631/67/1347 ; Androgen receptors ; Androgens ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Biomedical and Life Sciences ; Biomedicine ; Breast cancer ; Breast Neoplasms - drug therapy ; Breast Neoplasms - genetics ; Breast Neoplasms - metabolism ; Breast Neoplasms - surgery ; Cancer ; Cancer Research ; Chemotherapy ; Chemotherapy, Adjuvant ; Clinical trials ; Disease-Free Survival ; Drug Resistance ; Epidemiology ; ErbB Receptors - metabolism ; ErbB-2 protein ; Estrogens ; Female ; Gene expression ; Gene Expression Profiling ; Humans ; Immunohistochemistry ; Life Sciences ; Medical prognosis ; Medicin och hälsovetenskap ; Molecular Medicine ; Oncology ; Pharmaceutical sciences ; Pharmacology ; Progesterone ; Receptor, ErbB-2 - metabolism ; Receptors, Androgen - metabolism ; Receptors, Estrogen - metabolism ; Receptors, Progesterone - metabolism ; Survival ; Survival Rate ; Treatment Outcome ; Tumors</subject><ispartof>British journal of cancer, 2019-04, Vol.120 (9), p.913-921</ispartof><rights>Cancer Research UK 2019</rights><rights>This work is published under https://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>Attribution</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c592t-416bb8d97f0968a21a536cd948240c679f7e49d36eb9802c3fbc385101b2dd913</citedby><cites>FETCH-LOGICAL-c592t-416bb8d97f0968a21a536cd948240c679f7e49d36eb9802c3fbc385101b2dd913</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6734658/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6734658/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,552,727,780,784,885,27924,27925,41488,42557,51319,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30899086$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://hal.umontpellier.fr/hal-02282586$$DView record in HAL$$Hfree_for_read</backlink><backlink>$$Uhttp://kipublications.ki.se/Default.aspx?queryparsed=id:140804644$$DView record from Swedish Publication Index$$Hfree_for_read</backlink></links><search><creatorcontrib>Bonnefoi, Hervé</creatorcontrib><creatorcontrib>MacGrogan, Gaetan</creatorcontrib><creatorcontrib>Poncet, Coralie</creatorcontrib><creatorcontrib>Iggo, Richard</creatorcontrib><creatorcontrib>Pommeret, Fanny</creatorcontrib><creatorcontrib>Grellety, Thomas</creatorcontrib><creatorcontrib>Larsimont, Denis</creatorcontrib><creatorcontrib>Bécette, Véronique</creatorcontrib><creatorcontrib>Kerdraon, Olivier</creatorcontrib><creatorcontrib>Bibeau, Frédéric</creatorcontrib><creatorcontrib>Ghnassia, Jean-Pierre</creatorcontrib><creatorcontrib>Picquenot, Jean-Michel</creatorcontrib><creatorcontrib>Thomas, Jeremy</creatorcontrib><creatorcontrib>Tille, Jean-Christophe</creatorcontrib><creatorcontrib>Slaets, Leen</creatorcontrib><creatorcontrib>Bodmer, Alexandre</creatorcontrib><creatorcontrib>Bergh, Jonas</creatorcontrib><creatorcontrib>Cameron, David</creatorcontrib><creatorcontrib>EORTC 10994/BIG 1-00 study investigators</creatorcontrib><creatorcontrib>and on behalf of the EORTC 10994/BIG 1-00 study investigators</creatorcontrib><title>Molecular apocrine tumours in EORTC 10994/BIG 1-00 phase III study: pathological response after neoadjuvant chemotherapy and clinical outcomes</title><title>British journal of cancer</title><addtitle>Br J Cancer</addtitle><addtitle>Br J Cancer</addtitle><description>Background
We explored, within the EORTC10994 study, the outcomes for patients with molecular apocrine (MA) breast cancer, and defined immunohistochemistry (IHC) as androgen-receptor (AR) positive, oestrogen (ER) and progesterone (PR) negative. We also assessed the concordance between IHC and gene expression arrays (GEA) in the identification of MA cancers.
Methods
Centrally assessed biopsies for AR, ER, PR, HER2 and Ki67 by IHC were classified into six subtypes: MA, triple-negative (TN) basal-like, luminal A, luminal B HER2 negative, luminal B HER2 positive and “other”. The two main objectives were the pCR rates and survival outcomes in the overall MA subtype (and further divided by HER2 status) and the remaining five subtypes.
Results
IHC subtyping was obtained in 846 eligible patients. Ninety-three (11%) tumours were classified as the MA subtype. Both IHC and GEA data were available for 64 patients. In this subset, IHC concordance was 88.3% in identifying MA tumours compared with GEA. Within the MA subtype, pCR was observed in 33.3% of the patients (95% CI: 29.4–43.9) and the 5-year recurrence-free interval was 59.2% (95% CI: 48.2–68.6). Patients with MA and TN basal-like tumours have lower survival outcomes.
Conclusions
Irrespective of their HER2 status, the prognosis for MA tumours remains poor and adjuvant trials evaluating anti-androgens should be considered.</description><subject>631/67/1347</subject><subject>Androgen receptors</subject><subject>Androgens</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Biomedical and Life Sciences</subject><subject>Biomedicine</subject><subject>Breast cancer</subject><subject>Breast Neoplasms - drug therapy</subject><subject>Breast Neoplasms - genetics</subject><subject>Breast Neoplasms - metabolism</subject><subject>Breast Neoplasms - surgery</subject><subject>Cancer</subject><subject>Cancer Research</subject><subject>Chemotherapy</subject><subject>Chemotherapy, Adjuvant</subject><subject>Clinical trials</subject><subject>Disease-Free Survival</subject><subject>Drug Resistance</subject><subject>Epidemiology</subject><subject>ErbB Receptors - metabolism</subject><subject>ErbB-2 protein</subject><subject>Estrogens</subject><subject>Female</subject><subject>Gene expression</subject><subject>Gene Expression Profiling</subject><subject>Humans</subject><subject>Immunohistochemistry</subject><subject>Life Sciences</subject><subject>Medical prognosis</subject><subject>Medicin och hälsovetenskap</subject><subject>Molecular Medicine</subject><subject>Oncology</subject><subject>Pharmaceutical sciences</subject><subject>Pharmacology</subject><subject>Progesterone</subject><subject>Receptor, ErbB-2 - metabolism</subject><subject>Receptors, Androgen - metabolism</subject><subject>Receptors, Estrogen - metabolism</subject><subject>Receptors, Progesterone - metabolism</subject><subject>Survival</subject><subject>Survival Rate</subject><subject>Treatment Outcome</subject><subject>Tumors</subject><issn>0007-0920</issn><issn>1532-1827</issn><issn>1532-1827</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>C6C</sourceid><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>D8T</sourceid><recordid>eNp1Uk1v1DAQjRCIbgs_gAuyxAUOoWPHcWwOSGVV2pUWVULlbDmOs8mS2MFOFu2f6G_G2922tFJPHs-8N58vSd5h-Iwh46eBYopZClikQAmk2xfJDOcZSTEnxctkBgBFCoLAUXIcwjp-BfDidXKUARfRZLPk5ofrjJ465ZEanPatNWicejf5gFqLzq9-Xs8RBiHo6bfFBcIpABoaFQxaLBYojFO1_YIGNTauc6tWqw55EwZnI0DVo_HIGqeq9bRRdkS6Mb0bG-PVsEXKVkh3rb0luWnUrjfhTfKqVl0wbw_vSfLr-_n1_DJdXl0s5mfLVOeCjGmcuix5JYoaBOOKYJVnTFeCckJBs0LUhaGiypgpBQeis7rUGc8x4JJUlcDZSZLu84a_ZphKOfi2V34rnWrlwfU7WkZSHofnES-exQ_eVQ-kOyKmwIEySiP3654bAb2ptLGjV93jFI8itm3kym0kKzLK8l3xT_sEzRPa5dlS7nxACCc5Z5vdYB8Pxbz7M5kwyr4N2nSdioeYgiRYsDz2dtvXhyfQdTy7jWuXhOCC5jxneUThPUp7F4I39X0HGOROhXKvQhlVKHcqlNvIef__xPeMO9lFADmsM4bsyviH0s9n_QdKvukp</recordid><startdate>20190430</startdate><enddate>20190430</enddate><creator>Bonnefoi, Hervé</creator><creator>MacGrogan, Gaetan</creator><creator>Poncet, Coralie</creator><creator>Iggo, Richard</creator><creator>Pommeret, Fanny</creator><creator>Grellety, Thomas</creator><creator>Larsimont, Denis</creator><creator>Bécette, Véronique</creator><creator>Kerdraon, Olivier</creator><creator>Bibeau, Frédéric</creator><creator>Ghnassia, Jean-Pierre</creator><creator>Picquenot, Jean-Michel</creator><creator>Thomas, Jeremy</creator><creator>Tille, Jean-Christophe</creator><creator>Slaets, Leen</creator><creator>Bodmer, Alexandre</creator><creator>Bergh, Jonas</creator><creator>Cameron, David</creator><general>Nature Publishing Group UK</general><general>Nature Publishing Group</general><general>Cancer Research UK</general><scope>C6C</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7TO</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB0</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>1XC</scope><scope>VOOES</scope><scope>5PM</scope><scope>ADTPV</scope><scope>AOWAS</scope><scope>D8T</scope><scope>ZZAVC</scope></search><sort><creationdate>20190430</creationdate><title>Molecular apocrine tumours in EORTC 10994/BIG 1-00 phase III study: pathological response after neoadjuvant chemotherapy and clinical outcomes</title><author>Bonnefoi, Hervé ; MacGrogan, Gaetan ; Poncet, Coralie ; Iggo, Richard ; Pommeret, Fanny ; Grellety, Thomas ; Larsimont, Denis ; Bécette, Véronique ; Kerdraon, Olivier ; Bibeau, Frédéric ; Ghnassia, Jean-Pierre ; Picquenot, Jean-Michel ; Thomas, Jeremy ; Tille, Jean-Christophe ; Slaets, Leen ; Bodmer, Alexandre ; Bergh, Jonas ; Cameron, David</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c592t-416bb8d97f0968a21a536cd948240c679f7e49d36eb9802c3fbc385101b2dd913</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>631/67/1347</topic><topic>Androgen receptors</topic><topic>Androgens</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Biomedical and Life Sciences</topic><topic>Biomedicine</topic><topic>Breast cancer</topic><topic>Breast Neoplasms - drug therapy</topic><topic>Breast Neoplasms - genetics</topic><topic>Breast Neoplasms - metabolism</topic><topic>Breast Neoplasms - surgery</topic><topic>Cancer</topic><topic>Cancer Research</topic><topic>Chemotherapy</topic><topic>Chemotherapy, Adjuvant</topic><topic>Clinical trials</topic><topic>Disease-Free Survival</topic><topic>Drug Resistance</topic><topic>Epidemiology</topic><topic>ErbB Receptors - metabolism</topic><topic>ErbB-2 protein</topic><topic>Estrogens</topic><topic>Female</topic><topic>Gene expression</topic><topic>Gene Expression Profiling</topic><topic>Humans</topic><topic>Immunohistochemistry</topic><topic>Life Sciences</topic><topic>Medical prognosis</topic><topic>Medicin och hälsovetenskap</topic><topic>Molecular Medicine</topic><topic>Oncology</topic><topic>Pharmaceutical sciences</topic><topic>Pharmacology</topic><topic>Progesterone</topic><topic>Receptor, ErbB-2 - metabolism</topic><topic>Receptors, Androgen - metabolism</topic><topic>Receptors, Estrogen - metabolism</topic><topic>Receptors, Progesterone - metabolism</topic><topic>Survival</topic><topic>Survival Rate</topic><topic>Treatment Outcome</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Bonnefoi, Hervé</creatorcontrib><creatorcontrib>MacGrogan, Gaetan</creatorcontrib><creatorcontrib>Poncet, Coralie</creatorcontrib><creatorcontrib>Iggo, Richard</creatorcontrib><creatorcontrib>Pommeret, Fanny</creatorcontrib><creatorcontrib>Grellety, Thomas</creatorcontrib><creatorcontrib>Larsimont, Denis</creatorcontrib><creatorcontrib>Bécette, Véronique</creatorcontrib><creatorcontrib>Kerdraon, Olivier</creatorcontrib><creatorcontrib>Bibeau, Frédéric</creatorcontrib><creatorcontrib>Ghnassia, Jean-Pierre</creatorcontrib><creatorcontrib>Picquenot, Jean-Michel</creatorcontrib><creatorcontrib>Thomas, Jeremy</creatorcontrib><creatorcontrib>Tille, Jean-Christophe</creatorcontrib><creatorcontrib>Slaets, Leen</creatorcontrib><creatorcontrib>Bodmer, Alexandre</creatorcontrib><creatorcontrib>Bergh, Jonas</creatorcontrib><creatorcontrib>Cameron, David</creatorcontrib><creatorcontrib>EORTC 10994/BIG 1-00 study investigators</creatorcontrib><creatorcontrib>and on behalf of the EORTC 10994/BIG 1-00 study investigators</creatorcontrib><collection>SpringerOpen</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>ProQuest Nursing and Allied Health Journals</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>ProQuest Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>ProQuest Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>British Nursing Database</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection (Proquest) (PQ_SDU_P3)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Biological Sciences</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>Biological Science Database</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>Hyper Article en Ligne (HAL)</collection><collection>Hyper Article en Ligne (HAL) (Open Access)</collection><collection>PubMed Central (Full Participant titles)</collection><collection>SwePub</collection><collection>SwePub Articles</collection><collection>SWEPUB Freely available online</collection><collection>SwePub Articles full text</collection><jtitle>British journal of cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Bonnefoi, Hervé</au><au>MacGrogan, Gaetan</au><au>Poncet, Coralie</au><au>Iggo, Richard</au><au>Pommeret, Fanny</au><au>Grellety, Thomas</au><au>Larsimont, Denis</au><au>Bécette, Véronique</au><au>Kerdraon, Olivier</au><au>Bibeau, Frédéric</au><au>Ghnassia, Jean-Pierre</au><au>Picquenot, Jean-Michel</au><au>Thomas, Jeremy</au><au>Tille, Jean-Christophe</au><au>Slaets, Leen</au><au>Bodmer, Alexandre</au><au>Bergh, Jonas</au><au>Cameron, David</au><aucorp>EORTC 10994/BIG 1-00 study investigators</aucorp><aucorp>and on behalf of the EORTC 10994/BIG 1-00 study investigators</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Molecular apocrine tumours in EORTC 10994/BIG 1-00 phase III study: pathological response after neoadjuvant chemotherapy and clinical outcomes</atitle><jtitle>British journal of cancer</jtitle><stitle>Br J Cancer</stitle><addtitle>Br J Cancer</addtitle><date>2019-04-30</date><risdate>2019</risdate><volume>120</volume><issue>9</issue><spage>913</spage><epage>921</epage><pages>913-921</pages><issn>0007-0920</issn><issn>1532-1827</issn><eissn>1532-1827</eissn><abstract>Background
We explored, within the EORTC10994 study, the outcomes for patients with molecular apocrine (MA) breast cancer, and defined immunohistochemistry (IHC) as androgen-receptor (AR) positive, oestrogen (ER) and progesterone (PR) negative. We also assessed the concordance between IHC and gene expression arrays (GEA) in the identification of MA cancers.
Methods
Centrally assessed biopsies for AR, ER, PR, HER2 and Ki67 by IHC were classified into six subtypes: MA, triple-negative (TN) basal-like, luminal A, luminal B HER2 negative, luminal B HER2 positive and “other”. The two main objectives were the pCR rates and survival outcomes in the overall MA subtype (and further divided by HER2 status) and the remaining five subtypes.
Results
IHC subtyping was obtained in 846 eligible patients. Ninety-three (11%) tumours were classified as the MA subtype. Both IHC and GEA data were available for 64 patients. In this subset, IHC concordance was 88.3% in identifying MA tumours compared with GEA. Within the MA subtype, pCR was observed in 33.3% of the patients (95% CI: 29.4–43.9) and the 5-year recurrence-free interval was 59.2% (95% CI: 48.2–68.6). Patients with MA and TN basal-like tumours have lower survival outcomes.
Conclusions
Irrespective of their HER2 status, the prognosis for MA tumours remains poor and adjuvant trials evaluating anti-androgens should be considered.</abstract><cop>London</cop><pub>Nature Publishing Group UK</pub><pmid>30899086</pmid><doi>10.1038/s41416-019-0420-y</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0007-0920 |
| ispartof | British journal of cancer, 2019-04, Vol.120 (9), p.913-921 |
| issn | 0007-0920 1532-1827 1532-1827 |
| language | eng |
| recordid | cdi_swepub_primary_oai_swepub_ki_se_481098 |
| source | PubMed (Medline); MEDLINE; SpringerLink; SWEPUB Freely available online; EZB Electronic Journals Library |
| subjects | 631/67/1347 Androgen receptors Androgens Antineoplastic Combined Chemotherapy Protocols - therapeutic use Biomedical and Life Sciences Biomedicine Breast cancer Breast Neoplasms - drug therapy Breast Neoplasms - genetics Breast Neoplasms - metabolism Breast Neoplasms - surgery Cancer Cancer Research Chemotherapy Chemotherapy, Adjuvant Clinical trials Disease-Free Survival Drug Resistance Epidemiology ErbB Receptors - metabolism ErbB-2 protein Estrogens Female Gene expression Gene Expression Profiling Humans Immunohistochemistry Life Sciences Medical prognosis Medicin och hälsovetenskap Molecular Medicine Oncology Pharmaceutical sciences Pharmacology Progesterone Receptor, ErbB-2 - metabolism Receptors, Androgen - metabolism Receptors, Estrogen - metabolism Receptors, Progesterone - metabolism Survival Survival Rate Treatment Outcome Tumors |
| title | Molecular apocrine tumours in EORTC 10994/BIG 1-00 phase III study: pathological response after neoadjuvant chemotherapy and clinical outcomes |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T20%3A12%3A13IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_swepu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Molecular%20apocrine%20tumours%20in%20EORTC%2010994/BIG%201-00%20phase%20III%20study:%20pathological%20response%20after%20neoadjuvant%20chemotherapy%20and%20clinical%20outcomes&rft.jtitle=British%20journal%20of%20cancer&rft.au=Bonnefoi,%20Herv%C3%A9&rft.aucorp=EORTC%2010994/BIG%201-00%20study%20investigators&rft.date=2019-04-30&rft.volume=120&rft.issue=9&rft.spage=913&rft.epage=921&rft.pages=913-921&rft.issn=0007-0920&rft.eissn=1532-1827&rft_id=info:doi/10.1038/s41416-019-0420-y&rft_dat=%3Cproquest_swepu%3E2196514044%3C/proquest_swepu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2217458565&rft_id=info:pmid/30899086&rfr_iscdi=true |